Q2 EPS Estimate for Vigil Neuroscience Increased by Analyst

Vigil Neuroscience, Inc. (NASDAQ:VIGL - Free Report) - Investment analysts at Wedbush increased their Q2 2025 earnings per share estimates for Vigil Neuroscience in a report issued on Wednesday, May 7th. Wedbush analyst L. Chico now forecasts that the company will earn ($0.39) per share for the quarter, up from their previous estimate of ($0.43). Wedbush currently has a "Outperform" rating and a $13.00 target price on the stock. The consensus estimate for Vigil Neuroscience's current full-year earnings is ($2.07) per share. Wedbush also issued estimates for Vigil Neuroscience's Q3 2025 earnings at ($0.41) EPS, Q4 2025 earnings at ($0.42) EPS, FY2025 earnings at ($1.70) EPS, Q1 2026 earnings at ($0.38) EPS, Q2 2026 earnings at ($0.40) EPS, Q3 2026 earnings at ($0.44) EPS, Q4 2026 earnings at ($0.47) EPS, FY2026 earnings at ($1.70) EPS, FY2027 earnings at ($1.53) EPS and FY2028 earnings at ($0.17) EPS.

Several other analysts also recently issued reports on VIGL. HC Wainwright reduced their price target on Vigil Neuroscience from $17.00 to $14.00 and set a "buy" rating for the company in a research note on Friday, March 14th. Guggenheim reissued a "buy" rating on shares of Vigil Neuroscience in a report on Friday, January 24th. Finally, William Blair upgraded Vigil Neuroscience to a "strong-buy" rating in a research report on Thursday, April 24th. Four research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, Vigil Neuroscience has a consensus rating of "Buy" and an average price target of $16.25.

Vigil Neuroscience Stock Up 0.4%

VIGL stock opened at $2.42 on Monday. Vigil Neuroscience has a twelve month low of $1.31 and a twelve month high of $6.06. The business has a 50 day moving average price of $1.93 and a two-hundred day moving average price of $2.30. The company has a market cap of $112.95 million, a price-to-earnings ratio of -1.17 and a beta of 1.90.

Vigil Neuroscience (NASDAQ:VIGL - Get Free Report) last released its quarterly earnings results on Wednesday, May 7th. The company reported ($0.49) EPS for the quarter, topping analysts' consensus estimates of ($0.53) by $0.04.

Institutional Investors Weigh In On Vigil Neuroscience

Several hedge funds have recently added to or reduced their stakes in VIGL. Blair William & Co. IL lifted its stake in shares of Vigil Neuroscience by 219.1% in the 1st quarter. Blair William & Co. IL now owns 1,033,577 shares of the company's stock valued at $1,840,000 after acquiring an additional 709,677 shares during the last quarter. Woodline Partners LP grew its holdings in shares of Vigil Neuroscience by 239.1% during the 4th quarter. Woodline Partners LP now owns 488,756 shares of the company's stock worth $831,000 after acquiring an additional 344,614 shares during the period. Squarepoint Ops LLC purchased a new position in shares of Vigil Neuroscience during the 4th quarter worth approximately $193,000. Two Sigma Advisers LP boosted its position in shares of Vigil Neuroscience by 243.8% in the 4th quarter. Two Sigma Advisers LP now owns 69,100 shares of the company's stock worth $117,000 after purchasing an additional 49,000 shares in the last quarter. Finally, Two Sigma Investments LP boosted its position in shares of Vigil Neuroscience by 44.0% in the 4th quarter. Two Sigma Investments LP now owns 136,920 shares of the company's stock worth $233,000 after purchasing an additional 41,836 shares in the last quarter. Institutional investors own 83.64% of the company's stock.

About Vigil Neuroscience

Vigil Neuroscience, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Its lead candidate is VGL101(Iluzanebart), a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.